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1. Introduction
In adult central (CNS) and peripheral nervous system (PNS), intermediate filaments (IFs) are
the most abundant cytoskeletal components [1]. Neurons express differentially several IF pro‐
teins depending on their developing stage or their localization in the nervous system. In CNS,
IFs are principally composed of the neurofilament (NF) triplet proteins (called NFL (light, 68
kDa), NFM (medium, 160 kDa) and NFH (heavy, 205 kDa); type IV) and α-internexin (66 kDa;
type IV), while in the PNS, NFs are made up of NFL, NFM, NFH and peripherin (57 kDa; type
III) [2, 3]. Neurons may also express other IF proteins, including nestin (200 kDa; type IV),
vimentin (57 kDa, type III) syncoilin isoforms (Sync1 (64 kDa), Sync2 (64 kDa); type III) and
synemin isoforms (Low synemin (41 kDa), Middle or beta synemin (150 kDa), High or alpha
synemin (180 kDa); type IV). While present in perikarya and dendrites, IFs are particularly
abundant in large myelinated axons, where they are essential for axon radial growth during
development and axon caliber maintenance [4]. Consequently they are crucial to optimize the
conduction velocity of the nerve impulse. They also contribute to the dynamic properties of
the axonal cytoskeleton during neuronal differentiation, axon outgrowth, regeneration and
guidance [5]. The IF proteins share a common tripartite structure with a globular head, a central
α-helical rod domain and variable tail domains that differ in length and amino acids compo‐
sition. The central rod domain of approximately 310 amino acids contains four α-helical re‐
gions and is involved in the assembly of 10 nm filaments [6]. NFM and NFH subunits differ
from other neuronal IF proteins by their long tail domains containing numerous repeats of
Lys-Ser-Pro (KSP) phosphorylation sites [4].
An increasing body of evidence supports the view that the most common mechanism of
chronic neurodegenerative disorders involves abnormal protein production, processing or
misfolding and subsequent accumulation in nervous system. Alterations in the metabolism
and/or organization of neuronal IFs are frequently associated, directly or indirectly, with var‐
ious neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Charcot-Mar‐
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ie-Tooth (CMT) disease, giant axonal neuropathy ( GAN), neuronal intermediate filament
inclusion disease (NIFID), Parkinson disease (PD), diabetic neuropathy, dementia with Lewy
bodies and spinal muscular atrophy [7]. While IF abnormalities in neurodegenerative disor‐
ders could simply reflect a pathological consequence of neuronal dysfunction, recent studies
using transgenic mouse models suggested that IF disorganization itself can also produce del‐
eterious effects and therefore could contribute to the neurodegeneration process. Glial IF, and
more particularly GFAP in astrocytes, is also the target of mutations leading to neurodege‐
nerative diseases. Astrocytes express various IF proteins, including nestin, vimentin and syn‐
emin, but GFAP is the most abundant. GFAP is a type III IF protein existing under different
spliced forms. The relative abundance of these GFAP transcripts is variable and can be de‐
pendent upon astrocyte location or pathological states [8]. GFAP mutations lead to accumu‐
lations of GFAP protein and cause Alexander disease (AXD), a rare leukodystrophy. Here, we
tempted to cover the current knowledge related to neuronal and glial IF involvement in human
neurodegenerative diseases (Table 1).
Disease Mutations in IF
genes
Accumulation of IFs Possible causes of IF
accumulation
Possible roles of IF in
disease pathogenesis
ALS - Only 3 variants
identified in NEFH
gene.
- Peripherin
mutations
identified in 3
sporadic ALS
patients.
Accumulation of
peripherin and
extensively
phosphorylated NFs in
the perikaryon of motor
neurons and in axonal
spheroids.
- Defect of axonal transport
caused by abnormal
phosphorylation of NFs and/or
alteration of the molecular
motors.
- Modification of NF
stoichiometry.
- Alteration of post-translational IF
proteins modifications.
Paradoxically, perikaryal NF
aggregates appeared
protective in mouse models
of ALS, slowing disease
progression in these
animals.
- NFs may act as calcium
chelators or
phosphorylation sink.
- Removal of NFs from the
axonal compartment could
enhance axonal transport.
CMT 20 mutations in the
NEFL gene have
been linked to
CMT2E and CMT1F
(represent ≈ 2% of
CMT cases).
- Axonal swellings
containing disorganized
NFs.
- In vitro, co-expression
of most NFL mutants
with Wt NFM or NFH
results in the formation
of aggregates within the
cell body.
- Most mutated NFL proteins fail
to self-assemble or co-assemble
with Wt subunits, and affect
axonal transport of Wt and
mutant NFs.
- Mutations of heat-shock protein
can also cause NFL aggregate.
- Perturbation of the
axonal transport by
trapping molecular motors
and organelles in the cell
body.
- Alteration of
mitochondrial morphology
and dynamic.
GAN No - Enlarged axons filled
with abnormally packed
NFs.
- An acceleration of NF transport
concomitant with a normal rate of
NF protein synthesis and insertion
into transport system would lead
- Perturbation of the
axonal transport.
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Disease Mutations in IF
genes
Accumulation of IFs Possible causes of IF
accumulation
Possible roles of IF in
disease pathogenesis
- Generalized
aggregation of other
neuronal and non-
neuronal IFs.
to the formation of distal axonal
swelling with packed NFs.
- Disturbed cytoskeleton
regulation and modulation.
NIFID No Neuronal cytoplasmic
inclusions containing all
type IV neuronal IFs, and
especially α-internexin.
Not determined. Not determined. Abnormal
accumulation of IFs may
only be a secondary
phenomenon.
PD A point mutation in
the NEFM gene was
reported in only
one case of PD with
early onset.
Cytoplasmic inclusion
bodies (Lewy bodies)
composed of α-synuclein,
NF proteins, ubiquitin
and proteasome
subunits. Inappropriate
phosphorylation and
proteolysis of NFs occur
in Lewy bodies.
Not determined. Data suggest no direct
implication of IFs in
pathogenesis of PD.
AXD ≈ 100 mutations in
the GFAP gene
were identified in
AXD patients. ≈
95% of AXD cases
are due to GFAP
mutation.
Presence of protein
aggregates (Rosenthal
fibers) composed of
GFAP, αB-crystallin,
HSP27 and ubiquitin
within the cytoplasm of
astrocytes throughout
the CNS.
-Decreased degradation of GFAP.
- Up-regulation of αB-crystallin
and HSP27 are associated to the
aggregation of GFAP.
- Some mutations could impair
interaction of GFAP with partners
which normally prevent its
assembly, resulting in the
accumulation of GFAP polymers.
- Insufficient amount of plectin
seems promote GFAP aggregates.
The specific aspects of
astrocytes functions that
are compromised by the
mutations of GFAP have
not yet been discovered,
but inhibited proteasome
activity and activated stress
pathways seemed to be
important consequences of
GFAP accumulation.
Table 1. IFs in neurodegenerative diseases.
2. Neuronal intermediate filaments and neurodegenerative diseases
2.1. Amyotrophic lateral sclerosis
ALS, also referred to as Lou Gehrig's disease, is a neurodegenerative disease which, by affect‐
ing the motor neurons in the motor cortex, brain stem and spinal cord, causes progressive
physical impairment, together with worsening limitations in the functions of breathing, swal‐
lowing and communication. The disease has an incidence rate of 1-2 per 100,000, with a higher
occurrence in men than in women. There is no cure and death usually occurs within 3 to 5
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years from symptom onset. Only 10% of cases are inherited in an autosomal dominant pattern
with the remaining 90% sporadic. 20% of all the familial cases are due to mutations in Cu/Zn
superoxide dismutase 1 (SOD1), the most abundant cytosolic enzyme.
One common pathological finding of both sporadic and familial ALS is the accumulation of
NFs and/or peripherin in the perikaryon of motor neurons and in axonal spheroids [9]. Because
of the presence of IF proteins in these aggregates, several studies have searched for mutations
in genes coding for NF proteins and peripherin. The discovery of a small number of NF gene
variants in ALS patients suggested the involvement of NFs in the pathogenesis of the disease.
Indeed, codon deletions or insertions in the KSP repeat motifs of NFH have been identified in
patients with sporadic ALS [10-12]. However, two others studies failed to identify such var‐
iants in the NF genes linked to sporadic and familial ALS [13, 14], suggesting that mutations
in the NF genes are not a systematic common cause of ALS but could be a risk factor for sporadic
ALS. Peripherin mutations have also been identified in three sporadic ALS patients [15-17],
including a frameshift mutation in the PRPH gene able to disrupt the NF network assembly
in vitro, reinforcing the view that NF disorganization may contribute to pathogenesis. These
results suggest that peripherin mutations may be responsible for a small percentage of ALS
cases. Two peripherin isoforms have been linked to ALS: aggregate-inducing Per28 is upre‐
gulated in patients with ALS, at both the mRNA and protein levels, and an antibody specific
for Per28 stained the filamentous inclusions [18]. The Per61 splice variant is neurotoxic and
has been observed in ALS mouse models and human patients [19]. These observations raise
the possibility that missplicing of peripherin could lead to disease. It is also of interest to note
the presence of high NFL and NFH levels and auto-antibodies against NFL in cerebrospinal
fluid of ALS patients [20-22]. Furthermore, plasma NFH levels closely reflect later stages of
disease progression and therapeutic response in a mouse model of ALS [23]. In the same way,
a significant relation exists between cerebrospinal fluid NFL levels and disease progression in
ALS patients [24]. Accordingly, it seems that NFs levels may be valuable biomarkers of later
disease progression in ALS.
NFs found in perikaryal aggregates are extensively phosphorylated, a process that occurs
normally only within the axon [25]. The mechanisms governing the formation of IF aggregates
are still not clearly established but defects of axonal transport or abnormal stoichiometry of IF
proteins could be involved. Perturbations of the axonal transport of NFs and organelles are
one of the earliest pathological changes seen in several transgenic mouse models of ALS
[26-29]. The premature phosphorylation of NF tail-domains in motor neurons cell bodies could
directly mediate their accumulation in this region. Glutamate excitotoxicity, another patho‐
genic process in ALS, may induce this abnormal phosphorylation of NFs. Treatment of primary
neurons with glutamate activates members of the mitogen-activated protein kinase family
which phosphorylate NFs with ensuing slowing of their axonal transport [30]. In addition,
glutamate leads to caspase cleavage and activation of protein kinase N1 (PKN1), a NF head-
rod domain kinase [31]. This cleaved form of PKN1 disrupts NF organization and axonal
transport. Excitotoxicity mediated by non-N-methyl-D-aspartic acid (NMDA) receptor is also
associated with the aberrant colocalization of phosphorylated and dephosphorylated NF pro‐
teins [32]. Inhibition of Pin1, a prolyl isomerase, was suggested as a possible therapeutic target
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to reduce pathological accumulation of phosphorylated NFs. Pin1 associates with phosphory‐
lated NFH in neurons and is found in aggregates in spinal cord from ALS patients [33]. Its
inhibition by inhibitor or down-regulating Pin1 levels reduces glutamate-induced perikaryal
accumulation of phosphorylated NFH. Finally, riluzole protects against glutamate-induced
slowing of NF axonal transport by decreasing perikaryal NF side-arm phosphorylation [34],
probably via the inhibition of ERK and p38 activities, two NF kinases activated in ALS.
Alterations of the anterograde or retrograde molecular motors may also be responsible for
aggregation of IFs. Mutation of dynein or p150glued [35], overexpression of dynamitin [36] and
absence of kinesin heavy chain isoform 5A (KIF5A) [37] induce NF accumulations in mice.
Recent studies suggest that inhibition of retrograde transport is more susceptible to cause
accumulation of NFs than inhibition of anterograde transport. The inhibition of dynein by
increasing the level of dynamitin induces aberrant focal accumulation of NFs within axonal
neurites whereas inhibition of kinesin inhibits anterograde transport but does not induce sim‐
ilar focal aggregations [38]. Similarly, the neuron-specific expression of Bicaudal D2 N-termi‐
nus (BICD2-N), a motor-adaptor protein, impairs dynein-dynactin function, causing the
appearance of giant NF swellings in the proximal axons [39]. However these mice did not
develop signs of motor neuron degeneration and motor abnormalities.
Modification in NF stoichiometry was also proposed to induce accumulation of NFs. Sin‐
gly  overexpressing  any  of  the  NF  subunit  in  transgenic  mice  led  to  prominent  motor
neuropathy  characterized  by  the  presence  of  abnormal  NF  accumulations  resembling
those found in ALS [40-42]. Remarkably, the motor neuron disease caused by excess hu‐
man  NFH  (hNFH)  can  be  rescued  by  restoring  a  correct  stoichiometry  of  NF  subunits
via  the  overexpression  of  hNFL in  a  dosage-dependent  fashion  [43].  Overexpression  of
peripherin  in  mice  also  provokes  the  formation  of  cytoplasmic  protein  aggregates  and
the subsequent  selective  loss  of  motor  neurons  during ageing [44,  45].  This  loss  is  pre‐
ceded by axonal  transport  defects  and formation of  axonal  spheroids [46].  Because NFL
mRNA levels  are  reduced in  cases  of  ALS,  Beaulieu et  al.  [45]  generated double  trans‐
genic mice overexpressing peripherin and deficient for NFL (Per;NFL-/- mice).  Here, the
onset  of  peripherin-mediated  disease  is  accelerated  by  the  deficiency  of  NFL.  Without
NFL,  peripherin  interacts  with  NFM and NFH to  form disorganized IF  structures.  This
could  explain  why  the  number  of  IF  inclusion  bodies  is  increased  in  Per;NFL-/-  mice,
leading to  an earlier  neuronal  death and to  defects  of  fast  axonal  transport  in  cultured
Per;NFL-/-  neurons  [47].  In  contrast,  peripherin  toxicity  can  be  attenuated  by  coexpres‐
sion of NFL or NFH [48, 49], illustrating once again the importance of IF protein stoichi‐
ometry.  NFH  overexpression  shifted  the  intracellular  localization  of  inclusion  bodies
from  the  axonal  to  the  perikaryal  compartment  of  motor  neurons,  suggesting  that  the
toxicity  of  peripherin inclusions may be related to their  axonal  localization,  possibly by
altering the axonal  transport.  However,  it  should be  noted that  peripherin  is  not  a  key
contributing factor to the neuronal  death in disease caused by SOD1 mutations because
absence  or  overexpression  of  peripherin  in  SOD1G37R  mice  do  not  affect  the  onset  and
progression of motor neuron disease [50].
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Changes in stoichiometry were reported in ALS motor neurons as the levels of NFL, α-inter‐
nexin and peripherin mRNA are decreased, while in familial ALS the levels of peripherin
mRNA appear to be abnormally elevated [51-53]. This suggests a change in the stoichiometry
of cytoskeletal protein expression which could be conducive to the formation of neurofila‐
mentous aggregates in ALS. This decrease of IF mRNA could be due in part to modification
in their stability. Several NFL mRNA binding proteins have been identified in human, includ‐
ing 14-3-3 proteins [54], TAR (trans-active regulatory) DNA-binding protein (TDP43) [55], both
mutant and wild-type SOD1 [56] and Rho guanine nucleotide exchange factor (RGNEF) [57].
These proteins are incorporated in ALS intraneuronal aggregates and affect the stability of
NFL mRNA. Mice expressing human TDP-43 displayed reduced NF mRNAs and proteins
contents, inducing a decrease of caliber of their motor axons [58]. The involvement of TDP-43
in ALS pathogenesis was reinforced by the recent discovery of several mutant forms of this
protein in familial and sporadic ALS [59]. Motor neurons from mice expressing such mutated
TDP-43 displayed peripherin and NFs (NFM and NFH) aggregates, concomitant with a down‐
regulation of NFL and an overexpression of peripherin [60]. In addition, they detected in these
mice the presence of abnormal splicing variants of peripherin, such as Per61, that can contrib‐
ute to formation of IF aggregates. RGNEF is another RNA binding protein that acts as an NFL
mRNA stability factor via 3′ untranslated region destabilization and reduces NFL protein lev‐
els when overexpressed in a stable cell line. Furthermore, RGNEF cytoplasmic inclusions were
detected in ALS spinal motor neurons that colocalized with ubiquitin, p62/sequestosome-1,
and TDP-43 [61]. These observations provide a possible mechanism for NF aggregate forma‐
tion together with a link between ALS and Rho signaling pathways.
Neuronal IF abnormalities in ALS may also occur as a result of post-translational protein
modifications. Indeed, advanced glycation endproducts were detected in NF aggregates of
motor neurons in familial and sporadic ALS [62]. O-glycosylation of NFM is strongly decreased
in spinal cord of different models for ALS, whereas phosphorylation is increased relative to
total NFM [63, 64], suggesting competition of the binding sites of these two modifications and
a potential mechanism for the formation of NF protein accumulations in ALS. Interestingly,
inhibition of O-GlcNAcase (OGA), the enzyme catalyzing removal of O-GlcNAc, increased
levels of O-GlcNAc modified NFM in spinal cords of control mice, but not in mutant SOD1
mice. Moreover, phosphorylation state of NFM appeared unchanged in these mutant mice [64].
The authors speculate that this lack of difference in NFM phosphorylation in mutant SOD1
mice may arise from the aggregation of hyperphosphorylated NFs, which may prevent de‐
phosphorylation and subsequent O-GlcNAc modification. It was also showed that SOD1 can
catalyze nitration of tyrosines by peroxynitrite in the rod and head domains of NFL [65].
However, no significant changes were detected in the nitration of NFL isolated from cervical
spinal cord tissue of sporadic ALS cases [66].
Finally,  it  seems that  non-neuronal  cells  could  be  directly  involved in  the  formation  of
cytoskeletal  aggregates  within  proximal  axon  from  motor  neurons.  Indeed,  cultured
mouse spinal motor neurons in contact with non-neuronal cells displayed swellings that
were morphologically and neurochemically comparable to axonal spheroids that develop
in  vivo  in  ALS  transgenic  mouse  models  [67].  These  swellings  contained  NFL,  NFM,
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NFH,  α-internexin  and  peripherin,  and  induced  the  accumulation  of  mitochondria  and
vesicle-like structures, suggesting a disruption of the axonal transport. Moreover, the se‐
verity of this axonopathy correlated with the phenotype of the glial cells,  with a signifi‐
cant increase being induced by a glial feeder layer expressing mutant SOD1 or that was
pre-aged prior to plating the motor neurons [67].
To further determine whether NFs are directly involved in SOD1-mediated disease, mice ex‐
pressing mutant SOD1 were mated with transgenic mice deficient for axonal NFs. The with‐
drawal of NFs from the axonal compartment and their perikaryal accumulation induced by
the expression of NFH-β-galactosidase fusion protein conferred no beneficial effect to
SOD1G37R mice [68], indicating that axonal NFs are not necessary for SOD1-mediated disease.
This was also observed in SOD1G85R mice deprived of NFL, but the absence of axonal NFs in
these animals prolongs their life span by approximately 15% [69]. Surprisingly, overexpression
of mouse NFL or mouse NFH in SOD1G93A mice [70], and overexpression of hNFH in
SOD1G37R mice [71], also increase their life span by respectively 15% and 65%. This suggests a
protective effect of NF perikaryal accumulation in motor neuron disease caused by mutant
SOD1. While the mechanism of protection is unclear, it seems that perikaryal accumulation of
NFs rather than their axonal deficiency is responsible for slowing disease in these models.
Indeed, the formation of large perikaryal aggregates and a massive depletion of axonal NFs
due to the expression of the human NFH43 allele cause more positive effects than human
NFH44 allele which induces smaller aggregates and more axonal NFs [71]. Moreover, the dis‐
ruption of one allele for each NF gene induces a 40% decrease of axonal NF proteins content
and an important axonal atrophy without perikaryal accumulation of NFs in SOD1G37R mice,
but it does not extend their life span nor does it alleviate the loss of motor axons [72]. Several
hypotheses were proposed to explain this protective effect of perikaryal aggregates in SOD1-
mediated disease. Through their multiple calcium-binding sites NFs may act as calcium che‐
lators. Supporting this hypothesis, a significant neuroprotection was obtained by
overexpressing the calcium-binding protein calbindin-D28k in cultured motor neurons [73].
It was also proposed that perikaryal accumulations of NFs in motor neurons may alleviate
ALS pathogenesis by acting as a phosphorylation sink for cyclin-dependent kinase 5 dysre‐
gulation induced by mutant SOD1, thereby reducing the excessive phosphorylation of tau and
other neuronal substrates [72]. This was supported by the fact that NF accumulations contain
hyperphosphorylated NFM and NFH subunits in ALS patients [25] and in SOD1 mutant mice
[74]. However, removal of NFM and NFH sidearms led to a delay of disease in SOD1 mutant
mice rather than the acceleration predicted by a kinase dysregulation model [75], indicating
that perikaryal phosphorylation of NFs is not an essential contributor to reduced toxicity of
SOD1 mutants and that abnormal phosphorylation of NF proteins may be a detrimental factor.
Alternatively, axonal removal of NFs could enhance axonal transport, which is impaired in
SOD1 mice, by providing a more flexible axoplasm.
Finally, it was shown that NFs are involved in the localization of NMDA receptors in the
neuronal plasma membrane by interacting with the NMDA NR1 subunit [76]. Thus, accumu‐
lation of NFs could interfere with glutamate receptor function and prevent glutamate excito‐
toxicity. However, NF aggregate-bearing neurons demonstrate increased intracellular calcium
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levels and enhanced cell death in response to NMDA receptor activation without increased
NMDA receptor expression. These results suggest that the presence of NF aggregates renders
motor neurons more susceptible to NMDA-mediated excitotoxicity [77].
2.2. Charcot-Marie-Tooth disease
CMT represents a heterogeneous group of inherited peripheral neuropathies affecting both
motor and sensory neurons to the muscles. CMT is the most common inherited disorder of the
PNS, with approximately 1 per 2,500 people affected. Patients slowly lose function of their feet/
legs and hand/arms as nerves to the extremities degenerate. First signs typically appear in the
first or second decade of life, although it may be detected in infancy. This disease shows a high
degree of heterogeneity, both in the clinical presentation and at the genetic level. CMT was
originally subclassified into CMT1 and CMT2 on the basis of electrophysiological properties
and histopathology. CMT1 is a demyelinating disease with reduced nerve conduction velocity
whereas CMT2 is an axonal neuropathy with relatively normal nerve conduction velocity.
CMT patients show a high degree of heterogeneity, due to mutations in multiple genes. This
led to the distinction of other subtypes of CMT, including CMT3 (or Dejerine-Sottas disease,
a particularly severe demyelinating form of CMT), CMT4 (autosomal recessive form of de‐
myelinating CMT) and CMTX (X-linked form of CMT with both demyelinating and axonal
features). Moreover, each type of CMT has several subtypes.
Vogel et al. [78] reported the presence of NF accumulations in CMT. Evidence for the involve‐
ment of IFs in the pathogenesis of CMT was provided by the identification of 20 mutations of
the NEFL gene on chromosome 8 in patients with CMT1F and CMT2E. Mutations in NEFL
gene are responsible for approximately 2% of CMT cases and a high percentage of CMT2 cases.
These mutations are located throughout the three functional domains of this protein (head,
rod and tail) and consist of substitutions, deletions and frame-shift mutations. Co-expression
of most NFL mutants with wild-type NFM or NFH subunits disrupted the NF cytoskeleton in
vitro, resulting in the formation of aggregates within the cell body [79, 80]. The first two CMT-
associated NEFL mutations, NFLP8R and NFLQ333P, were identified in respectively a Belgian and
a Russian family. In addition to disturb the assembly of NFs, these mutations affect the axonal
transport of wild-type and mutant NFs, but also the transport of mitochondria and human
amyloid β protein precursor, resulting in alterations of retrograde axonal transport, fragmen‐
tation of the Golgi apparatus and increased neuritic degeneration [79, 80]. The effect of these
mutant proteins on filament assembly was dominant, since wild-type NFL could not rescue
the assembly defect. Filament formation was also abolished in SW13 cells by the rod domain
A148V mutation [81]. These data provide possible mechanisms by which these mutants could
be involved in axonal degeneration and CMT pathogenesis.
The Pro-22 residue of NFL is also the target of several mutations: P22R, P22S and P22T.
The P22R mutation, identified in a Korean family, is associated with demyelinating neu‐
ropathy features  of  CMT1F [82].  The  P22S substitution was  first  described in  a  Sloven‐
ian  CMT2  family  [83],  then  in  an  Italian  family  developing  a  primary  axonopathy
characterized  by  giant  axons  with  swellings  composed  essentially  of  aggregated  NFs
[84].  Interestingly,  clinical  and electrophysiological  studies  from patients  with P22S mu‐
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tation  revealed  a  mixed  axonal  and  demyelinating  neuropathy  [85],  emphasizing  the
complexity of  genotype-phenotype correlations in CMT. Finally,  the P22T mutation was
detected in unrelated Japanese patients with CMT disease [86]. The formation of NF ag‐
gregates in patients expressing NFLP22S  and NFLP22T  mutant proteins could be explain by
the  ability  of  these  mutations  to  abolish  the  phosphorylation  of  the  adjacent  Thr21  by
cyclin-dependent  kinase  5,  which  normally  inhibits  filament  assembly  [87].  The  phos‐
phorylation of NFL head domain by PKA alleviated aggregates in cortical neurons, pro‐
viding a potential therapeutic approach to dissociate NF aggregates in CMT disease [87].
The screening of  323 patients  with CMT or related peripheral  neuropathies allowed the
identification of six disease-associated missense mutations and one 3-bp in-frame deletion
in the NEFL  gene [88]. Other mutations were also detected in Korean CMT patients [89],
in a German family [90], and four mutations in the head and rod domains of NFL, includ‐
ing a L268P substitution and a del322Cys_326 Asn deletion, were identified by the screen‐
ing of  177  patients  [91].  Most  of  these  mutated proteins  (except  E7K and D469N) form
aggregates,  and thus could alter  the axonal  transport  following their  abnormal aggrega‐
tion in cell bodies and axons. A duplication-insertion mutation of NFL in a patient with
CMT was  also  reported  [92],  which  probably  provoked  neuronal  degeneration  through
both  aggregation  and  destabilization  of  the  IF  network.  Finally,  new  mutations  in  the
NEFL  gene  were  identified  following  the  screening  of  223  Japanese  CMT patients  [93].
Four  heterozygous  missense  mutations  (P8L,  E90K,  N98S  and  E396K)  were  detected  in
five unrelated patients as well as a homozygous nonsense mutation (E140Stop) in one pa‐
tient. All these patients displayed moderate delayed nerve conduction velocities, possibly
caused by a loss of large diameter fibers. This study suggested that nonsense NEFL muta‐
tions probably cause a recessive phenotype, while missense mutations cause a dominant
phenotype [93].  The majority of  NFL mutations are linked to axonal  forms of  CMT but
their implication in demyelinating CMT cannot be excluded since nerves from patients ex‐
pressing NFLL268P or NFLE90K showed evidence of Schwann cell abnormalities [88, 91].
The first mouse model of the CMT2E disease expressed the hNFLP22S mutant protein specifi‐
cally in the nervous system and recapitulate many of the overt phenotypes observed in CMT2E
patients, including aberrant hind limb posture, motor deficits, hypertrophy of muscle fibres
and loss of muscle innervation without neuronal loss [94]. To address whether CMT2E disease
is potentially reversible, this mouse model was based on the tetracycline-responsive gene sys‐
tem that allows the suppression of mutant hNFLP22S expression in mature neurons through
administration of doxycycline. Remarkably, a 3-month treatment of these mice with doxycy‐
cline after disease onset efficiently down-regulated expression of hNFLP22S and reversed the
neurological phenotype [94], providing hope that future therapeutic strategies might not only
stop progress of CMT2E disease but also reverse it. A novel line of CMT2E mice that consti‐
tutively express hNFLE397K was recently generated [95]. As with the hNFLP22S mice, these mice
developed as early as 4 months signs consistent with CMT2E patients, such as aberrant hind
limb posture, digit deformities, reduced locomotor activity and reduced motor nerve conduc‐
tion velocities. However, some aspects differed between the two lines of CMT2E mice. Indeed,
hNFLE397K mice showed no significant denervation and their muscles were atrophied. More‐
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over, they showed only relatively mild signs of nerve pathology, including ectopic accumu‐
lations of phosphorylated NFs in motor neuron cell bodies, NF disorganization in motor and
sensory roots, and reduced axonal caliber [95]. The divergence in cellular pathology between
the two animal models may suggests that overt CMT2E phenotypes may arise through dif‐
ferent cellular mechanisms.
Mutations of myotubularin-related protein 2 (MTMR2) (CMT4B), heat-shock protein B1
(HSPB1) (CMT2F) or HSPB8 (CMT2L) can also cause NFL aggregation [96-99], indicating that
mutation of NFs is not the only mechanism inducing their accumulation in CMT. Co-expres‐
sion of Wt HSPB1 with P8R or Q333P CMT mutant NFL reduced their aggregation, induced
reversal of mutant NFL aggregates and decreased mutant NFL-induced loss of motor neuron
viability [100]. On the opposite, mutant HSPB1 was found to have an inhibitory effect on the
assembly of NFL in transfected cells. Zhai et al. [100] showed that deletion of NFL markedly
reduces degeneration and loss of motor neurons induced by mutant HSPB1. Finally, mice
expressing mutant HSPB1 throughout the nervous system showed axonal pathology in spinal
cord and peripheral nerve that was age-dependent, with evidence of impaired NF cytoskele‐
ton, associated with organelle accumulation. These data suggest that overexpression of mutant
HSPB1 in neurons is sufficient to cause pathological changes in mice that are seen in patients
with CMT. Mutant MTMR2 also induces abnormal NFL assembly in transfected cells [98] and
mice lacking MTMR2 develop a CMT-like neuropathy, including several characteristics of
dysmyelination [101]. A similar phenotype was observed following Schwann cell-specific
MTMR2 inactivation, whereas neuron-specific inactivation did not provoke myelin outfold‐
ings nor axonal defects, suggesting that loss of MTMR2 in Schwann cells, but not in motor
neurons, is both sufficient and necessary to cause CMT4B neuropathy [102]. In addition to
disrupt the NF network, recent studies showed that expression of NFLP8R or NFLQ333P in cul‐
tured motor neurons caused the rounding of mitochondria and decreased their rate of fusion
concomitant with increased motility [103, 104], indicating an important function of NFs in
mitochondrial dynamics. Cotransfection of HSPB1 helped to maintain normal NF network,
axonal caliber and mitochondrial morphology. On the other hand, the cotransfection of HSPA1
was effective in neurons expressing NFLQ333P, but not NFLP8R, suggesting that chaperone-based
therapies have potential for the treatment of CMT2E but their efficacy would depend on the
profile of HSPs induced and the type of NEFL mutation.
2.3. Giant axonal neuropathy
GAN is a rare progressive neurodegenerative disorder with early onset affecting both PNS
and CNS. Phenotypic variability has been reported but typical clinical features include distal
limb weakness, areflexia and a marked gait disturbance. The motor deficits encompass amyo‐
trophy, muscle weakness and evolve with skeletal deformations and loss of ambulation by the
adolescence. As the disorder progresses, CNS involvement includes electroencephalographic
abnormalities, mental retardation, speech defect, seizures and defective upper motor neuron
function. GAN is caused by mutations in the GAN gene encoding the ubiquitously expressed
protein gigaxonin. Gigaxonin belongs to a protein family that is characterized by an N-terminal
BTB (broad-complex, Tramtrack, and Bric a brac) domain and six kelch repeats [105]. BTB/
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kelch proteins are organizers of the cytoskeletal network and closely linked to the ubiquitin
degradation pathway. More than 45 distinct mutations of the gigaxonin have been identified
to date along the entire GAN gene in patients. By revealing a high instability of gigaxonin in
multiple lymphoblasts cell lines from unrelated patients, Cleveland et al. [106] showed that
GAN is caused by a loss of function of gigaxonin.
The major cytopathological hallmark of GAN is the presence of distal enlarged axons, also
called giant axons, filled with abnormally packed IFs associated with a reduced number of
MTs [107]. In contrast, axonal segments proximal to the swellings exhibit a reduced number
of NFs [108]. Disorganization and accumulation of other types of IFs are also found in skin
fibroblasts, Schwann cells and muscle fibers [109-111], suggesting a critical role of gigaxonin
in maintaining cytoskeletal architecture. A decreased inter-NF distance was observed in sural
nerve axons of a GAN patient and, more surprisingly, the mean diameter of NFs was increased
(12.4 nm in GAN compared with 10.1 nm in controls) [112]. Although the mechanism leading
to the distal axonal accumulation of NFs is still unclear, an acceleration of their axonal transport
was observed in optic nerve from experimentally induced GAN rat model, concomitant with
a proximal decreased content of NFs and their distal accumulation [113]. The authors proposed
that acceleration of NF transport in the presence of a normal rate of NF protein synthesis and
insertion into transport system would lead to the formation of distal axonal swellings with
packed NFs.
In order to determine how loss of gigaxonin’s function leads to GAN, mice deleted in exons
3-5 of the GAN gene (GANΔ3-5 mice) were produced [114]. These mice develop strong motor
deficits as early as 6 months of age, including reduction of spontaneous movement, bizarre
limb posture and overall weakness. However, they displayed normal life span and fertility,
and giant axons were never seen. Nevertheless these mice exhibited enlarged axons with
densely packed NF, leading to the segregation of axonal organelles, a feature characteristic of
human GAN pathology. This was accompanied by an axonal loss at the age of 9-12 months.
However, it should be noted that some null mice showed no overt neurological phenotypes,
suggesting that some genetic modifiers may exist [115]. Another mouse model with deletion
of exon 1 of the GAN gene was generated [116] which exhibited no overt phenotype over 15
months in contrast to GANΔ3-5 mice. Nevertheless, they developed aggregates composed of
non-phosphorylated NFH and α-internexin in cerebral cortex and thalamus. Small aggregates
of NFL and peripherin also formed in cell bodies of dorsal root ganglion neurons. Moreover,
increased levels of neuronal IF proteins were detected in various regions of the nervous system,
confirming the importance of gigaxonin in modulating the levels and organization of IF pro‐
teins. Given the very different phenotypes between these two GAN models, Ganay et al. [117]
conducted a behavioral analysis over a 72-week period in their own GANΔ3-5 mice as well as
in GANΔ3-5 mice developed by Ding et al [114]. Analysis performed on their own model re‐
vealed difference depending on the genetic background. Indeed, a mild but persistent motor
impairment was reported in the 129/SvJ genetic background, while C57BL/6 animals displayed
rather a deterioration of sensory functions. Despite the modest phenotypic manifestation and
no pronounced signs of neurodegeneration, these mice exhibited severe cytoskeletal altera‐
tions, including an increase in the diameter of NFs, an overt impairment in their orientation
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and a strikingly increased abundance of the three NF subunits. Finally, they tested motor
deficits in GANΔ3-5 mice produced by Ding et al [114] and detected no clinical signs within the
first year. This is consistent with a mild progression of the disease in mice and suggests that
the three existing models probably display a phenotype of similar intensity. Altogether, these
data shown that the absence of gigaxonin results in a milder version of the GAN disease in
mice at the behavioral level, associated with a severe disorganization of the NF network that
recapitulates what is observed in patients [117].
Gigaxonin  was  shown  to  be  a  direct  key  player  in  the  Ubiquitin  Proteasome  System
(UPS).  Indeed,  BTB-containing proteins,  including gigaxonin have been found to  be  the
substrate adaptors of Cul3-dependant E3 ubiquitin ligases, interacting with Cul3 and the
substrates  through the BTB and the C-terminal  domains,  respectively [118-120].  Gigaxo‐
nin was shown to promote the ubiquitin-mediated degradation of  its  three known sub‐
strates,  the  microtubule-associated protein  1B (MAP1B)  [121],  tubulin  folding cofactor  B
(TBCB)  [122]  and MAP1S (also  called  MAP8)  [114].  Disease  associated gigaxonin  muta‐
tions perturb its association with these partners while gigaxonin ablation results in their
accumulation [114, 122, 123]. This raised the possibility that IF accumulation in GAN re‐
sults from a MT reorganization/destabilization. However, it is intriguing to note that these
proteins have opposite  effects  on MT network:  MAP1B is  a  MT-stabilizing phosphopro‐
tein, whereas overexpression of TBCB depolymerizes MTs. Using primary fibroblasts de‐
rived from skin biopsies of multiple GAN patients with aberrant aggregates of vimentin,
Cleveland et al. [106] demonstrated that vimentin aggregation is greatly enhanced in con‐
ditions driving quiescence and is not caused by an abnormal accumulation of the tubulin
chaperone TBCB and its effect on MT stability. Moreover, the prolonged depletion of the
MT network did not induce GAN-like aggregates of vimentin in normal fibroblasts. These
results indicated that the generalized disorganization of IFs in GAN patients may not in‐
volve TBCB-mediated MT disassembly and must be regulated by a yet unidentified mech‐
anism  [106].  Recently,  proteomic  analysis  performed  in  fibroblasts  from  four  GAN
patients provided new insights into disease mechanisms [124]. Although the major role of
gigaxonin is reported to be degradation of cytoskeleton-associated proteins, the amount of
76 structural cytoskeletal proteins was unaltered. However, several proteins linked to reg‐
ulation of the cytoskeleton network were found to be upregulated or downregulated. The
authors speculated that in GAN, dysregulation of the cytoskeletal network is responsible
for formation of aggregates of IFs. In the case of fibroblasts, disturbed cytoskeletal regula‐
tion could lead to a hyperphosphorylation state of vimentin that results in massive depo‐
lymerization of  vimentin filaments and finally in collapse of  the vimentin network.  The
unpolymerized  filaments  are  collected  in  the  aggresome  near  the  nucleus  where  they
form the typical aggregates [124].
2.4. Neuronal intermediate filament inclusion disease
NIFID is a recently described uncommon neurological disorder of early onset with a hetero‐
geneous clinical phenotype, including sporadic fronto-temporal dementia associated with a
pyramidal and/or extrapyramidal movement disorder. The symptoms comprise behavioural
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and personality changes, which can be associated to memory loss, cognitive impairment, lan‐
guage impairment, hyperreflexia and motor weakness. Neuropathologically, NIFID is char‐
acterized by widespread degeneration of the frontal and temporal lobes. The cytopathological
characteristics consist of neuronal loss, gliosis, swollen neurons and presence of large inclu‐
sions in the cell body of many neurons that are immunoreactive for all of the class IV neuronal
IFs and especially in α-internexin [125, 126]. These inclusions of α-internexin but negative for
tau or synuclein distinguish NIFID from other disease that involve IF inclusions, such as syn‐
ucleinopathies (e.g., PD), tauopathies (e.g., AD and frontotemporal dementia), and motor
neuron disease. Although α-internexin has been observed in neuronal inclusions in other neu‐
rodegenerative disorders, it is generally a relatively minor component. This raises the question
whether α-internexin-positive neuronal inclusions in NIFID reflect any selective neuronal
dysfunction, and as such if they are associated with some specific clinical symptoms. Genetic
screening revealed no pathogenic variants for all type IV neuronal IFs, SOD1, NUDEL and
gigaxonin [127, 128]. To date, no genetic mutations leading to NIFID have been described.
Interestingly,  the number of IFs aggregates is  high in areas with reduced neuronal loss,
and low in sites  of  intense neuronal  degeneration.  Cairns et  al.  [125]  proposed that  the
formation of  these inclusions is  an early event  in  the pathogenesis  of  NIFID,  and these
aggregates are then released and degraded into the extracellular space following degen‐
eration of the neuron. The mechanism of IF aggregation and the role they play in neuro‐
nal  dysfunction and cell  death are still  unclear.  Although immunoreactivity for  IFs  was
initially described as the defining pathological feature of NIFID, not all the inclusions in
NIFID are IF-positive. It now appears that aggregates of FUS (fused in sarcoma) protein,
is  a  more  consistent  feature  of  NIFID.  Indeed,  intracellular  accumulations  of  FUS  are
more  often  encountered  than  IF  inclusions  and all  neurons  that  contained abnormal  IF
aggregates  also  contained FUS inclusions  [129].  It  should also  be  noted that  clusters  of
FUS-immunoreactive  inclusions  are  larger  than  those  revealed  by  NFH  or  α-internexin
[130].  The authors  interpreted this  finding as  suggesting that  FUS plays  a  more  central
role in the pathogenesis of NIFID and that the abnormal accumulation of IFs is likely a
secondary  phenomenon.  It  now  remains  to  determine  the  exact  implication  of  FUS  in
the pathogenesis of NIFID.
2.5. Diabetic neuropathy
Diabetes is the leading cause of peripheral neuropathy worldwide. About 60 to 70 percent of
people with diabetes have some form of neuropathy. People with diabetes can develop nerve
problems at any time, but risk rises with age and longer duration of diabetes. Diabetic neuro‐
pathies are complex, heterogeneous disorders that affect dorsal root ganglia and sensory axons
more so than motor fibers. Nerve damage is likely due to a combination of factors, including
metabolic factors (e.g., high blood glucose, abnormal blood fat levels), neurovascular factors
leading to damage to the blood vessels, autoimmune factors, lifestyle factors and inherited
traits that increase susceptibility to nerve disease. Although its pathogenesis has not been fully
elucidated, diabetic neuropathy is characterized by slower conduction velocity, impairment
of axonal transport, axonal atrophy and reduced capacity for nerve regeneration. All these
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features of nerve function depend on the integrity of the axonal cytoskeleton and particularly
on NFs. In agreement with this, multiple abnormalities of NF biology were identified in models
of diabetes. An impairment of the axonal transport of NFs, actin and tubulin concomitant with
a proximal increase and a distal decrease of axonal calibers were observed in rats with strep‐
tozotocin-induced diabetes and in BioBreeding rats (a model of spontaneous type I diabetes)
[131, 132]. The distal axonal atrophy is accompanied by a concomitant NF loss in this region
[133], and accumulations of highly phosphorylated NF epitopes are present in proximal axonal
segments of dorsal root ganglia sensory neurons from diabetic patients [134]. An increase of
NF phosphorylation, correlated with activation of JNK, was also detected in lumbar dorsal
root ganglia from rat models [135]. Finally, there were a substantial decline in the mRNA levels
of all three NF subunits as well as reduced NF numbers and densities within large myelinated
sensory of long-term diabetic models [136]. All these results suggest that NF abnormalities
may contribute to the development of diabetic neuropathy, or may be affected by this disease.
However, slowing of conduction velocity in diabetic models occurs much earlier than loss of
NF investment or axonal atrophy [136]. To further elucidate the contribution of NFs to diabetic
neuropathy pathogenesis, the effect of streptozotocin-induced diabetes was analyzed in NFH-
LacZ transgenic mice characterized by axons completely lacking NFs [137]. Interestingly, di‐
abetic mice lacking NFs developed progressive slowing of conduction velocity in their motor
and sensory fibres and displayed decreased nerve action potential amplitudes earlier than
diabetic mice with normal IF cytoskeleton. Moreover, superimposing diabetes on axons with‐
out NFs also accentuated axonal atrophy. Administration of insulin that restored normogly‐
cemia reversed conduction slowing and restored sensory axon caliber. These findings indicate
that changes in NF expression, transport or post-translational modifications cannot account
alone for neurological features of diabetic neuropathy, but these IFs may help axons to better
resist the negative effects of diabetes [137].
2.6. Parkinson disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder after AD,
with a prevalence of about 2% among people over the age of 65 years. This disease is marked
by the depletion of dopaminergic melanin-containing neurons in the substantia nigra pars
compacta and a consequent loss of dopamine in the striatum. Another important pathological
feature is the presence, especially in substantia nigra pars compacta neurons, of eosinophilic
cytoplasmic inclusion bodies named Lewy bodies, composed of α-synuclein, NF proteins,
ubiquitin and proteasome subunits. Various features distinguish NFs in PD, including inap‐
propriate phosphorylation and proteolysis in Lewy bodies [138, 139], decreased NFL and NFH
mRNA levels [140], and reduced protein level of NFL and NFM [141]. A point mutation in the
NEFM gene was reported in a case of PD with early onset [142]. This mutation consisted in a
substitution of Ser for Gly at residue 336, a highly conserved region in the rod domain 2B of
NFM, and was argued to disrupt NF assembly. Although three other unaffected family mem‐
bers also carried this mutation, the authors had then proposed that aberrations in neuronal IFs
could lead to the development of the pathology seen in PD. However, the G336S mutation
does not disrupt the assembly and the distribution of NFs in vitro [143] and the screenings of
PD patients of similar or different ethnic background failed to identify this mutations [144,
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145], arguing against the implication of this NEFM mutation in pathogenesis of PD. Interest‐
ingly, research has shown that changes in the levels of NFL in the cerebrospinal fluid may be
used as a biomarker for the identification of PD [146] and that the serum levels of anti-NF
protein antibodies increase significantly in patients with PD [147]. Finally, it seemed that the
serum level of NFs in patients with PD was significantly correlated with duration of the disease
and age [148]. These findings support the idea that axonal injury causes the release of cytos‐
keleton proteins, and changes in the concentrations of serum NFs are probably related to the
severity of axonal injuries.
3. Glial intermediate filament GFAP and Alexander disease
Neuronal IFs are not the only class of IF to be responsible for the development of neurological
disorders. Glial IF can also be the primary cause of a CNS disorder. Indeed, GFAP, the major
constituent of astrocytic IFs, is directly involved in the development of the AXD. This disease
is a fatal, progressive white matter disorder that has been classified into three types based on
the age of onset: infantile, juvenile and adult. The infantile type, with onset between birth and
about two years of age, is the most frequent form of the disease and is fatal either within that
period or by around the age of 10 years. Clinical symptoms comprise progressive megalence‐
phaly, seizures and impaired cognitive function, which may be associated with ataxia and
hydrocephalus. Such phenotypes become progressively less common for the juvenile and adult
forms (for recent reviews, see [149, 150]). Both the infantile and juvenile forms usually appear
to be sporadic while the adult form is often familial.
AXD is a primary astrocytic disease and its manifestations are the result of astrocyte dysfunc‐
tions leading to both myelin damage and neuron dysfunction. Neuronal loss is often reported
but axons are relatively well preserved in demyelinated areas. The pathological hallmark of
AXD is the presence of protein aggregates known as Rosenthal fibers within the cytoplasm of
astrocytes throughout the CNS, but especially those located in the subpial, periventricular and
subependymal zones. Different constituents were identified in Rosenthal fibers: GFAP, αB-
crystallin, HSP27 and ubiquitin [151-153]. Although GFAP is also expressed in glial cells of the
PNS and in several other organs, Rosenthal fibers were not reported outside the CNS of AXD
patients.
To examine the function of GFAP in vivo, GFAP knock-out mice were generated [154-157].
These studies showed that mice lacking GFAP displayed astrocytes devoid of the IF, but still
developed and reproduced normally. Only subtle phenotypes emerged with age, arguing for
a role of GFAP in the white matter architecture, blood-brain barrier integrity, astrocyte-neu‐
ronal interactions and in modulating synaptic efficacy in the CNS [156, 157]. This is consistent
with the known roles of astrocytes that help to form blood brain barrier, promote synaptic
plasticity and coordinate neuronal activity. To determine the influence of increased GFAP
expression on astrocyte function, mice overexpressing the human GFAP gene were produced
[158]. Mice in the highest expressing lines developed a phenotype close to that observed in
AXD. Indeed, their brains contain many inclusion bodies indistinguishable from human
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Rosenthal fibers, astrocytes are hypertrophic and these animals died from an encephalopathy
at an age that is inversely correlated with the level of expression of the transgene. However,
no myelin abnormalities were observed. Microarray analysis performed on olfactory bulbs of
these animals recently highlighted the appearance of an initial stress response by astrocytes
which results in the activation of microglia and compromised neuronal function [159]. All these
results suggested that a primary alteration in GFAP may be responsible for AXD.
Sequence analysis of DNA samples from AXD patients was thus performed and revealed that
most cases are associated with mutations in the GFAP gene [160]. Since then, numerous mu‐
tations of this gene were identified; many of them being located in highly conserved domains
of the encoded protein that play specific roles in the assembly of IF network [8, 150]. It was
estimated that more than 95% of AXD cases are due to GFAP mutation. To date, all the iden‐
tified mutations are heterozygous and nearly all of them involve amino acid substitutions, but
several insertion or deletion/insertion alterations have also been reported (a continually up‐
dated list of all published mutations is maintained at the Waisman Center of the University of
Wisconsin-Madison; www.waisman.wisc.edu/alexander). Numerous mutations cluster in the
coils 1A and 2B of GFAP and two sites (R79 and R239) account for approximately half of all
patients affected. The comparison of mutations occurring in the various IF proteins revealed
that frequent mutations lying in the 2A segment seem to be unique to GFAP. It is possible that
molecular partners specifically interact with this region of GFAP but not with the equivalent
region of other IFs. The calcium-binding protein S100B binds to the N-terminal part of GFAP-
coil 2A [161]. As S100B prevents GFAP assembly [162], mutations in this domain could impair
GFAP-S100B interactions, resulting in the accumulation of GFAP polymers and possibly ag‐
gregates. It seems that a correlation exists between the different mutations and the severity of
the disease. However, there also exists significant phenotypic variability and age of onset for
the same mutation [163], suggesting that epigenetic and environmental factors influence the
appearance and timing of disease symptoms. It should also be noted that in rare cases of AXD,
no mutations in the GFAP gene has been found [164], indicating that there may be additional
causes of the disease.
The discovery of GFAP mutations led to the generation of knock-in mice with missense mu‐
tations homologous to those found in humans (R76H and R236H, which correspond to the
R79H and R239H mutations in human) [165, 166]. If the presence of mutant GFAP per se seemed
insufficient for aggregate formation, a 30% increase in GFAP content over that in wild-type
induced the formation of Rosenthal fibers in multiples sites throughout the CNS [166]. These
animals were also more susceptible to kainate-induced seizures. Nevertheless, they had a nor‐
mal lifespan, showed no overt behavioral defects and general white matter architecture and
myelination appeared normal. These features resemble those found in the adult form of AXD
rather than in the infantile form. This indicates that the presence of GFAP aggregates contain‐
ing mutant GFAP is not sufficient to induce a major phenotype of AXD, even though it causes
some abnormalities in the mouse. Interestingly, further elevation of GFAP via crosses to GFAP
transgenic animals led to a shift in GFAP solubility, an increased stress response, and ulti‐
mately death [165]. This correlates GFAP protein levels to the severity of the disease.
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While the genetic basis for AXD is now firmly recognized, there is little information con‐
cerning  the  mechanisms  by  which  GFAP  mutations  lead  to  disease.  Several  study
showed that  mutations  of  GFAP alters  the  normal  solubility  and organization of  GFAP
networks  [163,  167].  When  expressed  alone,  these  mutant  proteins  lost  their  ability  to
form filament in vitro.  But in presence of assembly partners, such as wild-type GFAP or
vimentin,  they  were  still  capable  of  incorporation  into  filament  networks  in  transfected
cells. If wild-type GFAP is prone to aggregate, mutations of GFAP exacerbates this accu‐
mulation [168]. Insufficient amounts of plectin, due to R239C GFAP expression, were al‐
so proposed to promote GFAP aggregation and Rosenthal fibers formation in AXD [169].
Both inhibited proteasome activity and activated stress pathways seemed to be important
consequences  of  GFAP  accumulation  [168].  As  a  positive  feedback  response,  both  the
proteasome hypofunction and JNK activation exacerbated GFAP accumulation, increasing
susceptibility of the cell to stressful stimuli. It thus appeared that accumulations of GFAP
protein would be more deleterious to the astrocytes than the mutant protein itself. How‐
ever, as a positive consequence, up-regulation of αB-crystallin and HSP27 were also asso‐
ciated  to  the  aggregation  of  GFAP  in  AXD  patients  [153,  170]  as  well  as  in  cell  and
animal models [159, 165, 168]. Increased αB-crystallin levels would contribute to the dis‐
aggregation  of  GFAP  aggregates  and  could  protect  cells  from  apoptotic  events  [171].
Moreover, a recent study demonstrated that AXD mutant GFAP accumulation stimulates
autophagy which in turn contributes to decrease GFAP levels [172]. The balance between
the  positive  and  negative  effects  of  GFAP  accumulation  might  define  the  survival  or
death of the cell. Compounds known to reduce GFAP expression in vitro, such as querce‐
tin,  might  be  useful  as  therapeutics.  For  instance,  treatment  with  the  antibiotic  ceftriax‐
one  alleviates  intracytoplasmic  aggregates  of  mutant  GFAP  by  inducing  the  up-
regulation  of  HSP27  and  αB-crystallin,  poly-ubiquitination  and  autophagy,  and  by
reducing the GFAP  promoter transcriptional regulation [173].  Curcumin was also report‐
ed to have beneficial effects in an in vitro model of AXD. Indeed, curcumin is able to in‐
duce  both  HSP27  and  αB-crystallin,  to  reduce  expression  of  both  RNA  and  protein  of
endogenous GFAP, to induce autophagy and, finally, to rescue the filamentous organiza‐
tion of the GFAP mutant protein, thus suggesting a role of this spice in counteracting the
pathogenic effects of GFAP mutations [174].
The GFAP gene is known to generate different splice variants, including the most abundant
isoform GFAP-α, and seven other differentially expressed transcripts including GFAP-δ (hu‐
man homologous GFAP-ε). GFAP-δ is incapable of self-assembly into IF per se, but can incor‐
porate a filament network composed of GFAP-α if the proportion of GFAP-δ to GFAP-α
remains <10% [175]. However, elevating the proportion of GFAP-δ perturbs association of αB-
crystallin with the IF fraction and induced IF bundling and aggregation in transiently trans‐
fected cells. Interestingly, GFAP-δ isoform is preferentially expressed in the same populations
of astrocytes that contain the most Rosenthal fibers in AXD. This raises the possibility that
GFAP-δ may play a key role in aggregate formation in combination with mutated GFAP. It
remains to determine whether GFAP-α:GFAP-δ ratio is perturbed in AXD tissues.
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4. Conclusion
IFs abnormalities are reminiscent in multiple human neurodegenerative disorders. Despite
extensive efforts over the past 40 years, processes leading to these abnormalities as well as
their precise contribution to disease pathogenesis often remain poorly understood. For in‐
stance, if it is clearly established that mutation in IF genes can be a primary cause of neurode‐
generative disorders, the question as to how they induce neurodegeneration frequently remain
unsolved. Although transgenic mouse models have been somewhat helpful in understanding
some mechanisms, most of these animals displayed a much less severe phenotype than patients
and results have not always been completely clear-cut. A growing body of evidence suggests
that perturbation of IF axonal transport and/or stoichiometry are directly involved in the for‐
mation of intracellular IF aggregates. Destabilization of IF mRNA could be responsible for
alteration in IF stoichiometry whereas aberrant post-translational modifications could affect
their transport. More investigations are also necessary to identify IF partners. The importance
of IF-associated proteins in the development of neurodegenerative disorders was also high‐
lighted by the identification of mutations in genes encoding IF partners that mimic IF-related
disease. This is particularly the case of gigaxonin in GAN. A particular attention should also
be paid to elucidate the role that IF proteins may play in signaling. Finally, it will be important
to elucidate why certain types of IF accumulations appear more toxic than others. While per‐
ikaryal accumulations are generally well tolerated, axonal inclusions are often noxious. The
more deleterious effect of axonal aggregates on axonal transport could be a promising avenue
to explore in the future and the identification of compounds able to remove these IF aggregates
is crucial to the development of new therapeutic approaches.
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